title: New and emerging concepts in soft tissue fillers: roundtable discussion.
abstract: In the years since the U.S. FDA approval in 2003 of the first hyaluronic acid (HA) filler, a number of other HA products have become available for use in the U.S., in addition to products composed of calcium hydroxylapatite (CaHA), poly-L lactic acid (PLLA) and polymethyl methacrylate (PMMA). This roundtable discussion between two US-based dermatologists, a European plastic surgeon, and a US-based plastic surgeon provides an overview of commonly used alloplastic filler products and examines how new strategies for soft tissue augmentation are developing as filler options continue to expand.
authors.affiliation: Sundaram Dermatology, Cosmetic & Laser Surgery, Fairfax, VA, USA. hemasundaram@gmail.com
authors.forename: Hema
authors.initials: H
authors.lastname: Sundaram
authors.forename: Timothy
authors.initials: T
authors.lastname: Flynn
authors.forename: Daniel
authors.initials: D
authors.lastname: Cassuto
authors.forename: Z Paul
authors.initials: ZP
authors.lastname: Lorenc
mesh_terms: D001672:Biocompatible Materials / Q000737:chemistry / Q000627:therapeutic use*; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use; D003357:Cosmetic Techniques; D017886:Durapatite / Q000627:therapeutic use; D005145:Face; D006801:Humans; D006820:Hyaluronic Acid / Q000737:chemistry / Q000627:therapeutic use*; D019344:Lactic Acid / Q000627:therapeutic use; D009465:Neuromuscular Agents / Q000627:therapeutic use; D011091:Polyesters; D011108:Polymers / Q000627:therapeutic use; D019904:Polymethyl Methacrylate / Q000627:therapeutic use; D012060:Rejuvenation; D015595:Skin Aging; D014783:Viscosity
chemical_list: D001672:Biocompatible Materials; D009465:Neuromuscular Agents; D011091:Polyesters; D011108:Polymers; D019344:Lactic Acid; C033616:poly(lactide); D006820:Hyaluronic Acid; D019904:Polymethyl Methacrylate; D017886:Durapatite; D019274:Botulinum Toxins, Type A